Pfizer Inc PFE

$30.42 +0.57 (1.91%)

Valuation

Market cap
170,135,264,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.87
Forward PE
10.22
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
28,703,300
Avg volume
32,172,113
Day's range
$29.88 – $30.44
Shares out
5,699,674,000
Stochastic %K
99%
Beta
0.32
Analysts
Sell
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

Fliptax Oct 23, 12:45 PM
$PFE https://seekingalpha.com/article/4949563-pfizer-poised-for-gains-with-a-new-drug-pipeline-and-cost-cutting-plans
0 replies
Parlandoconme Oct 23, 11:04 AM
$TOMZ currently at 9MIL in sales and pipe is filling up. easily hitting 12Mil in 2026 and 2027 probably going for 20MIL + $PFE and other biopharma loading up the truck. Dont buy high like ray,buying low is a better idea. that strategery has led to his mental breakdown
0 replies
TopOptionAlert Oct 23, 10:21 AM
$PFE NOV06 31C · still actionable Zone: $30.21 to $30.63 Invalidation: close under $29.25 Objectives: $32, then $34 The math: up 5.2% to the first objective and 11.8% to the second, against 3.8% risk on the invalidation, better than 3 to 1 to the second. Pfizer just printed a fresh 52 week high and almost nobody is talking about it, which is usually when a move still has room to run. This is a swing idea built around the November 3 earnings report, a morning the whole street has circled, because good numbers into a breakout tend to pull in all the money that was waiting for proof. Picture the $29.25 level as the floorboard you tap with your foot before you trust the whole room. If that floor holds, the walk toward $32 and then $34 is the same stairway this stock has been climbing all year. Where do you think the crowd shows up next? Right where the breakout gets its first headline. P.S. November 3 is the date to circle: Pfizer reports before the open, and this call expires three days later.
0 replies
thatsolardude365 Oct 23, 7:35 AM
$PFE: the Chantix math is tight. After $14.67M in fees, the consumer pool is capped near $5.84M for 3.58M claims A.B. Data is still reviewing. No pay date yet, claims closed. Open Class Actions.
0 replies
Diehard777 Oct 23, 3:42 AM
$PFE dammmm , This stock is going to be a money-making machine
1 replies
TopOptionAlert Oct 23, 12:39 AM
$PFE NOV06 30C · update Called at $29.44 on Oct 20, now $30.42 (plus 3.3%). The trade is working, with objectives at $31.25, then $33, and the invalidation at $28.85, a quiet staircase climb doing exactly what the plan asked. P.S. Watch $29.88, the old yearly high. Price closed above it, and holding there keeps the staircase intact.
0 replies
Itsokman Oct 22, 11:47 PM
$PFE RIPPING!!!!!!! Heh
0 replies
Diehard777 Oct 22, 11:07 PM 0 replies